摘要
目的:观察吉西他滨(泽菲)联合卡铂治疗Ⅲb或Ⅳ期初治非小细胞肺癌(NSCLC)的疗效和毒副作用。方法:初治的Ⅲb或Ⅳ期NSCLC46例,采用吉西他滨(泽菲)1200mg/m2,d1、d8,静滴;卡铂AUC=5,d1,静滴,21天为1个周期。结果:46例患者中,无CR病例,PR21例,SD20例,PD5例,客观有效率(CR+PR)为45.65%,中位生存期11.8个月,1年生存率35%(16/46),中位肿瘤进展时间7个月。毒副作用主要为中性粒细胞和血小板减少。结论:吉西他滨联合卡铂一线治疗晚期NSCLC有效率较高,有生存优势,毒副作用可耐受。
Objective：To evaluate the efficacy and toxicity of gemcitailne （GEM） plus carboplatin （CBP） in the treatment of the chemonaive patients with advanced non-small cell lung cancer （ NSCLC）. Methods ： Chemonaive patients with histological or cytological diagnosis of stage Ⅲ b or Ⅳ NSCLC were administrated with gemcitabine 1 200 mg/m^2 over 30 rain on days 1 and 8 and carbopl- atin AUC = 5.0 over 30 min on day 1 after the gemcitabine infusion. Treatment cycles were repeated every 21 days. Results：Of the 46 patients qualified for efficacy analysis, the overall response rate was 45.65% , including 21 eases of PR, 20 cases of SD and 5 cases of PD respectively. The median time to progression was 7 months and median survival time was 11.8 months. One-year survival rate were 35%. The predominant toxicity was hematologic, with neutropenia and thrombocytopenia. Conclusion： The GEM/CBP combination showed a high therapeutic response, an improved 1-year survival and well tolerated treatment for adyanced NSCLC.
出处
《临床肿瘤学杂志》
CAS
2006年第11期828-829,832,共3页
Chinese Clinical Oncology
关键词
晚期非小细胞肺癌
吉西他滨
卡铂
Advanced non-small cell lung cancer
Gemcitabine （GEM）
Carboplatin （CBP）
